Clinical Trials Logo
  1. Home
  2. Skin Pigmentation
  3. NCT01806831

Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment

Skin Irritation Clinical Trial

Official title:
Efficacy and Safety of Biocellulose Sheet From Coconut Juice Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment

Clinical Trial Summary

The laser areas treated with biocellulose sheet from coconut juice containing anti-hyperpigmentation agent ("biocellulose mask", "Farhorm®") heal faster than vaseline ointment which is a standard treatment.

Clinical Trial Description

Volar surface at upper arm (2X2 cm) on both sides were treated with semi ablative, 1,550 nm Erbium: glass fractional laser. Biocellulose sheet from coconut juice containing anti-hyperpigmentation agent ("biocellulose mask","Farhorm®")was applied for 20 min on one side and the other side was treated with vaseline ointment. The redness, skin hydration and skin pigmentation were evaluated at that area before laser, immediately after laser and after applying the treatment. These parameters were compared between treatment (area treated with Biocellulose sheet from coconut juice containing anti-hyperpigmentation agent, "biocellulose mask", "Farhorm®") and control (vaseline ointment). ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01806831
Study type Interventional
Source Chulalongkorn University
Contact
Status Completed
Phase N/A
Start date September 2012
Completion date June 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02297841 - Repeated Insult Patch Test of Personal Lubricants N/A
Completed NCT02968446 - Effect of Vitamin D After Application With Valchlor Early Phase 1
Completed NCT03397862 - A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System Phase 1
Unknown status NCT01821274 - A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design Phase 1
Completed NCT01892657 - Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test Phase 4
Withdrawn NCT02400320 - Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol Phase 4
Not yet recruiting NCT02645110 - Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations N/A
Completed NCT01892410 - Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash N/A
Completed NCT01887808 - Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30 N/A
Completed NCT01887860 - Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50 N/A
Completed NCT01888887 - Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser N/A
Completed NCT01892423 - Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion N/A